55 related articles for article (PubMed ID: 37597322)
1. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.
Gao M; Zhang D; Jiang C; Jin Q; Zhang J
Biomed Pharmacother; 2023 Oct; 166():115317. PubMed ID: 37597322
[TBL] [Abstract][Full Text] [Related]
2. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
3. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
4. Hepatoprotective effects of aspirin on diethylnitrosamine-induced hepatocellular carcinoma in rats by reducing inflammation levels and PD-L1 expression.
Wang Y; Wang M; Liu C; Hao M; Wang W; Li Y; Shi J; Zhang X; Dang S
Sci Rep; 2023 Dec; 13(1):21362. PubMed ID: 38049630
[TBL] [Abstract][Full Text] [Related]
5. Humanized disulfide-stabilized diabody against fibroblast growth factor-2 inhibits PD-L1 expression and epithelial-mesenchymal transition in hepatoma cells through STAT3.
Sun H; Song X; Li C; Li Q; Liu S; Deng N
IUBMB Life; 2023 Nov; 75(11):957-968. PubMed ID: 37489553
[TBL] [Abstract][Full Text] [Related]
6. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
7. [Apatinib Suppressed Macrophage-Mediated Malignant Behavior of Hepatocellular Carcinoma Cells via Modulation of VEGFR2/STAT3/PD-L1 Signaling].
Yin T; Fu CB; Wu DD; Nie L; Chen H; Wang Y
Mol Biol (Mosk); 2023; 57(4):706-708. PubMed ID: 37528791
[TBL] [Abstract][Full Text] [Related]
8. Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma.
Zhao T; Wei P; Zhang C; Zhou S; Liang L; Guo S; Yin Z; Cheng S; Gan Z; Xia Y; Zhang Y; Guo S; Zhong J; Yang Z; Tu F; Wang Q; Bai J; Ren F; Feng Z; Jia H
Elife; 2024 Mar; 12():. PubMed ID: 38441416
[TBL] [Abstract][Full Text] [Related]
9. Protein tyrosine phosphatase receptor type delta (PTPRD) suppresses the expression of PD-L1 in human hepatocellular carcinoma by down-regulating STAT3.
Meng Q; Tian J; Qin F; Huang X; Zhu D; Xiang B; Dong M
Transl Cancer Res; 2020 Sep; 9(9):5574-5584. PubMed ID: 35117921
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance.
Wang X; Ye X; Chen Y; Lin J
Int Immunopharmacol; 2023 Nov; 124(Pt A):110848. PubMed ID: 37633233
[TBL] [Abstract][Full Text] [Related]
11. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma.
Jia Y; Zhao J; Wang C; Meng J; Zhao L; Yang H; Zhao X
J Transl Med; 2024 Mar; 22(1):272. PubMed ID: 38475878
[TBL] [Abstract][Full Text] [Related]
12. [Formononetin enhances the antitumor effect of H22 hepatoma transplanted mice].
Li M; Jiang C; Chen J; Wang J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Dec; 39(12):1063-1068. PubMed ID: 38140864
[TBL] [Abstract][Full Text] [Related]
13. Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells.
Li N; Wang J; Zhang N; Zhuang M; Zong Z; Zou J; Li G; Wang X; Zhou H; Zhang L; Shi Y
Cancer Immunol Immunother; 2018 Feb; 67(2):271-283. PubMed ID: 29090321
[TBL] [Abstract][Full Text] [Related]
14. Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway.
Ji HF; Yang ZQ; Han JJ; Li HF; Jin ZQ; Chen WQ; Chen FH; Gong MC
Chin J Integr Med; 2024 Apr; 30(4):339-347. PubMed ID: 37943489
[TBL] [Abstract][Full Text] [Related]
15. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.
Zhou Z; Li X; Yang G; Wang J; Li B; Huang Y; Yan J; Tao K
Theranostics; 2023; 13(10):3371-3386. PubMed ID: 37351175
[No Abstract] [Full Text] [Related]
16. IRGM is a novel regulator of PD-L1 via promoting S6K1-mediated phosphorylation of YBX1 in hepatocellular carcinoma.
Ru J; Lu J; Ge J; Ding B; Su R; Jiang Y; Sun Y; Ma J; Li Y; Sun J; Xu G; Tong R; Zheng S; Yang B; Wu J
Cancer Lett; 2024 Jan; 581():216495. PubMed ID: 37993085
[TBL] [Abstract][Full Text] [Related]
17. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.
Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E
Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900
[TBL] [Abstract][Full Text] [Related]
18. Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.
Zhang F; Zhou K; Yuan W; Sun K
Nutr Cancer; 2024; 76(1):63-79. PubMed ID: 37909316
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of Xihuang pills' intervention in the tumour immune microenvironment for the treatment of liver cancer based on the STAT3-PDL1 pathway.
Wang Y; Wang W; Liu K; Liu Y; Shen X; Li Q; Deng F; Hao X; Wang Y
J Ethnopharmacol; 2024 Sep; 331():118278. PubMed ID: 38710457
[TBL] [Abstract][Full Text] [Related]
20. miR-429 inhibits the formation of an immunosuppressive microenvironment to counteract hepatocellular carcinoma immune escape by targeting PD-L1.
Yu X; Fan X; Zhang X; Wei P; Zhou H; Liu D; Chen B
Funct Integr Genomics; 2023 Sep; 23(4):312. PubMed ID: 37775648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
